CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187

https://doi.org/10.5281/zenodo.17069117

https://www.iajps.com/volumes/volume12-september-2025/07-issue-09-september-25/

Available online at: http://www.iajps.com *Review Article*

THE TRANSFERMATIVE IMPACT OF ARTIFICIAL INTELLEGENCE IN PHARMACEUTICAL INDUSTRY – AN OVERVIEW

Dr. P.Veera Lakshmi[1], Jethendra Lakshman Sai.S*[2], Bhavya Tejaswi.G[3], Aruna Kumari.K[4], Surya Kiran .M[5]

[1]Assistant Professor, School of Pharmaceutical sciences and Technologies, JNTUK, Kakinada, Andhra Pradesh, India

[2]*M.Pharm Student, Department of Pharmaceutics, School of Pharmaceutical Sciences and Technologies, JNTUK, Kakinada, Andhra Pradesh

Abstract:

This overview highlights the transformative impact of AI in the pharmaceutical industry, providing insights into current applications, technological advancements, and future directions aimed at reshaping drug discovery, development, and patient care. While addressing the need for ethical and regulatory frameworks to promote equitable and safe AI adoption, the current analysis focuses on the revolutionary potential of AI and examines its many important applications, prospects, and challenges in the pharmaceutical business. This paper provides information regarding artificial intelligence (AI), which plays a transformative role in various departments of the pharmaceutical industry both now and in the future.

Corresponding author:

Jethendra Lakshman sai.S*

E-mail: kerriarunakumari@gmail.com

Mobile no: 8074753577.

.

QR CODE

Please cite this article in ***press*** *Jethendra Lakshman sai.S et al.,* ***The Transfermative Impact Of Artificial Intellegence In Pharmaceutical Industry – An Overview****, Indo Am. J. P. Sci, 2025; 12(09).*

INTRODUCTION:

Artificial Intelligence (AI) is playing a transformative role in reshaping the pharmaceutical industry, bringing innovation, speed, and precision to processes that were once time-consuming and labour-intensive. The pharmaceutical sector has recently witnessed a transformative improvement and shift toward artificial intelligence (AI) in its drug and pharmaceutical delivery process and procedures (1). Artificial intelligence (AI) is revolutionizing the pharmaceutical industry at every stage of the drug lifecycle (2). The pharmaceutical industry is changing dramatically as a result of artificial intelligence (AI), which is bringing creativity, speed, and accuracy to previously labour-intensive and time-consuming procedures.

AI is transforming conventional workflows and establishing new benchmarks for efficacy and efficiency in a variety of areas, including medication research, clinical development, manufacturing, marketing, and regulatory affairs (3).

DRUG DISCOVERY:

Artificial Intelligence (AI) is transforming the field of drug discovery, providing ground-breaking approaches to speed up the creation of new therapeutics and tackle persistent challenges in the pharmaceutical sector. By utilizing sophisticated machine learning algorithms, computational models, and data analysis methods, AI has become an effective resource for improving the drug discovery process, refining target identification, and optimizing molecular design(4). In the realm of drug discovery, artificial intelligence employs predictive analytics to pinpoint prospective drug candidates, thereby minimizing the time and expenses related to conventional drug development (5). AI-driven computational chemistry and biology are transforming early drug discovery. Machine learning models (e.g. QSAR/QSPR, deep learning) now routinely predict drug–target interactions, optimize molecular structures, and prioritize candidates before laboratory testing.For example, one AI platform (PandaOmics/Chemistry42) recently identified a novel anti-fibrotic target and designed a potent inhibitor in about 18 months – a process that traditionally takes 5–15 years – at a fraction of the usual cost(6).



RESEARCH AND DEVELOPMENT:

Artificial Intelligence is essential in the creation and formulation of pharmaceuticals as it enhances the efficiency of new drug development. AI speeds up drug design by using predictive models to analyze molecular interactions, refining chemical structures, and discovering possible drug candidates(7). As AI continues to evolve, its role in pharmaceutical R&D is becoming even more critical, driving a shift toward more personalized, efficient, and data-driven drug development strategies. Ultimately, the integration of AI promises to deliver innovative therapies to patients faster, transforming the future of healthcare (8).

AI enables researchers to analyze massive biological datasets, predict molecular behavior, identify potential drug candidates, and optimize clinical trial designs with remarkable accuracy and speed. Machine learning algorithms can uncover hidden patterns in genomic, proteomic, and chemical data, allowing for the faster identification of therapeutic targets and the design of novel compounds. In preclinical research, AI assists in predicting drug safety and efficacy, reducing the need for extensive animal testing and minimizing early-stage failures.(9)

Furthermore, AI enhances clinical development by optimizing patient recruitment, improving trial monitoring, and enabling adaptive trial designs that respond in real time to data insights. These capabilities not only accelerate the drug development timeline but also significantly reduce costs and improve the chances of clinical success.

As AI continues to evolve, its role in pharmaceutical R&D is becoming even more critical, driving a shift toward more personalized, efficient, and data-driven drug development strategies. Ultimately, the integration of AI promises to deliver innovative therapies to patients faster, transforming the future of healthcare.



CLINICAL TRAILS:

Artificial intelligence is having a transformative impact on clinical trials by accelerating drug development, improving patient selection, enhancing data analysis, and reducing costs and timelines. These advances are reshaping how clinical research is conducted, with significant implications for efficiency and patient outcomes (10).

In clinical development, AI is making trials faster and more patient-centric, Machine learning which analyse electronic health records, genomics, and real-world data to match patients to trials and predict outcomes, improving recruitment and adherence (11). AI can automate the design and analysis of trials – from optimizing eligibility criteria to monitoring data quality – yielding more adaptive, efficient studies. One review notes that by enhancing patient selection and data analysis, AI "has the potential to accelerate trial cycles and patient outcomes"(12). AI systems can even auto-generate interim reports and flag anomalies, reducing human workload and errors (13).

During the COVID-19 pandemic, the industry's embrace of big data and AI surged, driving collaborations and proof-of-concepts (for example, the first AI-designed drugs have now entered clinical testing) (14) Overall, AI-enabled trials can cut delays and failures, yielding safe, effective therapies faster.

MANUFACTURING AND SUPPLY CHAIN:

AI is also streamlining pharmaceutical production and logistics. In manufacturing plants, machine learning monitors sensor data to predict equipment failures (predictive maintenance), automate control of synthesis and formulation, and enforce real-time quality control(15). For instance, AI can flag deviations on the production line and guide corrective action instantly, reducing downtime and human error. Advanced analytics optimize batch recipes and continuous manufacturing parameters to maximize yield and consistency(16,17).



In the supply chain, AI-driven forecasting predicts drug demand and optimizes inventory levels, while intelligent routing improves distribution efficiency. These capabilities enable "smoother, cost-effective, and efficient operations": inventory management and maintenance become predictive rather than reactive, lowering costs and risks. In emerging areas like 3D-printed personalized medicines, AI tailors printing parameters and drug-release profiles to individual needs, further increasing precision and affordability by embedding AI in manufacturing, companies can scale up production while maintaining compliance and quality (18,19)

MARKETING AND PATIENT ENGAGEMENT:

Artificial intelligence is reshaping how pharmaceutical firms interact with healthcare providers (HCPs) and patients. AI analytics ingest real-time market and feedback data to refine marketing strategies on the fly. For example, NLP models can process HCP survey responses or social media chatter in near-real time – a task that once took months – providing actionable insights within minutes (20).

This allows marketing teams to adjust messaging and campaigns dynamically to physician sentiment. AI also enables highly personalized engagement: predictive models can segment clinicians or patients by likely needs and behaviors, tailoring communication for greater relevance and adherence. In patient support programs, AI identifies individuals at risk of medication non-adherence by analyzing health records and socioeconomic factors Such tools then trigger customized interventions (reminders, education) to keep patients on therapy, thereby improving health outcomes. In short, AI-driven marketing and patient-engagement platforms help target the right audience with the right message at the right time, boosting both commercial efficiency and patient well-being (21).



REGULATORY AFFAIRS:

Regulators and compliance teams are increasingly using AI to manage complex data and ensure quality. Intelligent software can sift through vast regulatory and clinical data – such as trial datasets, manufacturing logs, and literature – to flag compliance issues or summarize findings. For example, AI tools can automatically check that documents meet regulatory standards, identify gaps in submissions, or alert reviewers to safety signals. This streamlines processes like clinical data management and submission writing, reducing errors and review time (15).

At the same time, regulators themselves are adapting. Agencies worldwide are crafting guidance for AI in pharma, advocating a risk-based approach to ensure that AI applications (in discovery, trials, manufacturing, or PV) meet established safety and efficacy criteria. In summary, AI is helping both companies and regulators maintain high standards more efficiently – from accurate documentation to automated quality checks – while highlighting the need for updated frameworks to oversee these new technologies (6).



PHARMACOVIGILANCE AND DRUG SAFETY

AI is transforming pharmacovigilance (PV) by automating and enhancing drug-safety monitoring. Machine learning and NLP can comb through safety databases, medical literature, and social media to detect adverse-event signals more quickly and accurately than manual review (22). Industry experts note that in 2024–25 companies are deploying AI to automate case intake, extract key data from reports, and expedite initial adverse event processing. Pilot studies show ML models identifying true safety signals earlier than traditional methods. These AI-driven surveillance systems can triage and prioritize cases, allowing pharmacovigilance teams to focus on high-risk issues. In turn, regulators monitor these developments: proactive use of AI for PV supports faster detection of potential drug harms, ultimately improving patient safety and regulatory compliance (23).



REFERENCES:

1. Sampene, A. K., & Nyirenda, F. (2024b). Evaluating the effect of artificial intelligence on pharmaceutical product and drug discovery in China. *Future Journal of Pharmaceutical Sciences*, *10*(1). https://doi.org/10.1186/s43094-024-00632-2
2. Saini, J. P. S., Thakur, A., & Yadav, D. (2025b). AI driven Innovations in Pharmaceuticals: Optimizing Drug Discovery and Industry Operations. *RSC Pharmaceutics*. https://doi.org/10.1039/d4pm00323c
3. Sci, C. S. F. P. (2018). Conference 2018: Translating Innovative Technology to Patient Care. An international symposium held jointly by CSPS, CSPT, and CC-CRS, May 22-25, 2018, Toronto, ON, Canada. *Journal of Pharmacy & Pharmaceutical Sciences*, *21*, 1s–162s. https://doi.org/10.18433/jpps30085
4. Prashant Singh, Asheesh Kumar Singh, Navneet Kumar Verma, Abhay Kumar, Zahra Chegini, Ankita Malviya. The Transformative Role of Artificial Intelligence in Pharmaceutical Healthcare: A Comprehensive Review. Sch Acad J Pharm, 2024 May 13(5): 139-144.
5. Salehi, F. (2024). The Transformative Role of Artificial Intelligence in the Healthcare Industry: A Comprehensive Analysis. Asian Journal of Research in Medicine and Medical Science, 6(1), 62–70.
6. Oualikene-Gonin W, Jaulent MC, Thierry JP, Oliveira-Martins S, Belgodère L, Maison P, Ankri J; Scientific Advisory Board of ANSM. Artificial intelligence integration in the drug lifecycle and in regulatory science: policy implications, challenges and opportunities. Front Pharmacol. 2024 Aug 2;15:1437167. doi: 10.3389/fphar.2024.1437167. PMID: 39156111; PMCID: PMC11327028.
7. Balisa Mosisa Ejeta, Malay K Das, Sanjoy Das, Fetene Fufa Bekere, Dubom Tayeng (2024). "Transformative Role of Artificial Intelligence in the Pharmaceutical Sector", Journal of Angiotherapy, 8(9),1-7,9933
8. Kolluri, S., Lin, J., Liu, R. *et al.* Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review. *AAPS J* **24**, 19 (2022). https://doi.org/10.1208/s12248-021-00644-3
9. The Transformative potential of artificialintelligence, Futures,Volume135,2022,102884, ISSN00163287,https://doi.org/10.1016/j.futures.2021.10288*(https://www.sciencedirect*.com/science/article/pii/S0016328721001932).
10. Wu G, Yang F. Navigating the Transformative Impact of Artificial Intelligence in Health

Services Research. Health Sci Rep. 2025 Jun 4;8(6):e70793. doi: 10.1002/hsr2.70793. PMID: 40475792; PMCID: PMC12138046.
11. Chopra H, Annu, Shin DK, Munjal K, Priyanka, Dhama K, Emran TB. Revolutionizing clinical trials: the role of AI in accelerating medical breakthroughs. Int J Surg. 2023 Dec 1;109(12):4211-4220. doi: 10.1097/JS9.0000000000000705. PMID: 38259001; PMCID: PMC10720846.
12. Askin S, Burkhalter D, Calado G, et al. Artificial Intelligence Applied to clinical trials: opportunities and challenges. Health Technol (Berl) 2023;13:203–213.
13. Saama Launches Industry's First AI-driven Data Platform to Accelerate Clinical Development | Saama - #1 in AI Clinical Analytics. Accessed 3 July 2023.
14. C. Malamateniou, S. McFadden, Y. McQuinlan, A. England, N. Woznitza, S. Goldsworthy, C. Currie, E. Skelton, K.-Y. Chu, N. Alware, P. Matthews, R. Hawkesford, R. Tucker, W. Town, J. Matthew, C. Kalinka, T. O'Regan,Artificial Intelligence: Guidance for clinical imaging and therapeutic radiography professionals, a summary by the Society of Radiographers AI working group,Radiography,Volume 27, Issue 2021,Pages 1192 1202,ISSN 1078-8174,https://doi.org/10.1016/j.radi.2021.07.028.
15. Jaskaran Preet Singh Saini , Ankita Thakur , Deepak Yadav -AI-driven innovations in pharmaceuticals: optimizing drug discovery and industry operations , 2025, 2, 437-454,DOI: 10.1039/D4PM00323C
16. Ubels J, Schaefers T, Punt C, Guchelaar HJ, de Ridder J. RAINFOREST: a random forest approach to predict treatment benefit in data from (failed) clinical drug trials. Bioinformatics.2020Dec 30;36(Suppl_2):i601-i609. doi: 10.1093/bioinformatics/btaa799. PMID: 33381829.
17. Ebube NK, Owusu-Ababio G, Adeyeye CM. Preformulation studies and characterization of the physicochemical properties of amorphous polymers using artificial neural networks. Int J Pharm. 2000 Feb 25;196(1):27-35. doi: 10.1016/s0378-5173(99)00405-6. PMID: 10675705.
18. Liu B, He H, Luo H, Zhang T, Jiang J. Artificial intelligence and big data facilitated targeted drug discovery. Stroke Vasc Neurol. 2019 Nov 7;4(4):206-213. doi: 10.1136/svn-2019-000290. PMID: 32030204; PMCID: PMC6979871.
19. Cirillo D, Valencia A. Big data analytics for personalized medicine. Curr Opin Biotechnol. 2019 Aug;58:161-167. doi: 10.1016/j.copbio.2019.03.004. Epub 2019 Apr 6. PMID: 30965188.
20. https://www.iqvia.com/blogs/2024/11/the-crucial-role-of-real-time-data-use-in-pharma-marketing
21. Miranda Schmalfuhs-Personalized AI-Powered Solutions for Better Patient Adherence ,December 4, 2024
22. De Abreu Ferreira R, Zhong S, Moureaud C, Le MT, Rothstein A, Li X, Wang L, Patwardhan M. A Pilot, Predictive Surveillance Model in Pharmacovigilance Using Machine Learning Approaches. Adv Ther. 2024 Jun;41(6):2435-2445. doi: 10.1007/s12325-024-02870-5. Epub 2024 May 5. PMID: 38704799; PMCID: PMC11133112.
23. Gosselt HR, Bazelmans EA, Lieber T, van Hunsel FPAM, Härmark L. Development of a multivariate prediction model to identify individual case safety reports which require clinical review. Pharmacoepidemiol Drug Saf. 2022;31(12):1300–1307. doi: 10.1002/pds.5553.